Literature DB >> 15696778

Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.

S Utsuki1, H Oka, Y Sato, N Kawano, B Tsuchiya, I Kobayashi, K Fujii.   

Abstract

Invasive meningioma shows benign histological features (WHO grade 1) and the brain expansion at the tumor-brain interface, and recurs more frequently than common meningiomas. To determine the mechanism of brain expansion, we studied the relationship between invasive meningioma and cell adhesion molecules. Immunostaining for E-cadherin (E-CH), N-cadherin (N-CH), beta-catenin, and Ki-67 was performed in 103 meningiomas that consisted of 61 meningothelial meningiomas, 25 fibrous meningiomas, 12 invasive meningiomas and 5 anaplastic meningiomas. All tumors were negative for N-CH. All the 61 meningothelial meningiomas, 10 of 12 invasive meningiomas, and 3 of 5 anaplastic meningiomas were positive for both E-CH and beta-catenin, while these were both negative in all of the fibrous meningiomas. In invasive meningiomas, the expansive part of the tumor showed a lower rate (4/12 tumors) of E-CH and beta-catenin positivity, while the central part showed a higher rate (10/12 tumors). The Ki-67 labeling index was higher in invasive and anaplastic meningiomas than in meningothelial meningiomas. These results suggest that a reduction in cell adhesion molecules and increased proliferative activity may be related, which may lead to a better understanding of the mechanism of meningioma expansion in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696778

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  9 in total

1.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Genetic and protein changes of E-cadherin in meningiomas.

Authors:  Nives Pećina-Slaus; Tamara Nikuseva Martić; Adam Jakov Deak; Martina Zeljko; Reno Hrasćan; Davor Tomas; Vesna Musani
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-12       Impact factor: 4.553

3.  The potential involvement of E-cadherin and beta-catenins in meningioma.

Authors:  Keiyu Zhou; Guangtao Wang; Yirong Wang; Hanghuang Jin; Shuxu Yang; Chibo Liu
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

4.  Meningiomas exhibit loss of heterozygosity of the APC gene.

Authors:  Nives Pećina-Slaus; Tamara Nikuseva Martić; Davor Tomas; Vili Beros; Martina Zeljko; Hrvoje Cupić
Journal:  J Neurooncol       Date:  2007-12-08       Impact factor: 4.130

5.  Invasive benign meningioma: Clinical characteristics, surgical strategies and outcomes from a single neurosurgical institute.

Authors:  Qingtang Lin; Feng Ling; Geng Xu
Journal:  Exp Ther Med       Date:  2016-04-04       Impact factor: 2.447

Review 6.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

Review 7.  Molecular neuropathology of brain-invasive meningiomas.

Authors:  Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

Review 8.  Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Mirna Lechpammer
Journal:  Cancers (Basel)       Date:  2016-07-15       Impact factor: 6.639

9.  Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study.

Authors:  Rehab Allah Ahmed; Abdelhadi M Shebl; Hany Onsy Habashy
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.